Philadelphia Chromosome-Negative Lymphoblastic Leukemia

1

Review clinical trials related to Philadelphia Chromosome-Negative Lymphoblastic Leukemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

ALL Backbone in AYAs

The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). The names of the study drugs involved in this study are: * blinatumomab (a type of immunotherapy drug) * cyclophosphamide (a type of chemotherapy drug) * cytarabine (a type of antineoplastic agent) * dexamethasone (a type of synthetic glucocorticoid) * doxorubicin (a type of antineoplastic agent) * etoposide (a type of antineoplastic agent) * mercaptopurine (a type of antineoplastic agent) * methotrexate (a type of chemotherapy drug) * pegaspargase (a type of antineoplastic agent) * vincristine (a type of antineoplastic agent)

Participants needed: 67
Trial details
Phase: Phase 2Age: 18-51Biological sex: AllType: InterventionalSponsor: Dana-Farber Cancer InstituteUpdated: Nov 12, 2025
Eligibility criteria

Diagnosis should be made by peripheral blood, bone marrow aspirate, bone marrow... [+4]